|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith RA, Brooks D, Cokkinides V, Saslow D
and Brawley OW: Cancer screening in the United States, 2013: A
review of current American Cancer Society guidelines, current
issues in cancer screening, and new guidance on cervical cancer
screening and lung cancer screening. CA Cancer J Clin. 63:88–105.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miska EA: How microRNAs control cell
division, differentiation and death. Curr Opin Genet Dev.
15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wozniak M, Mielczarek A and Czyz M: miRNAs
in Melanoma: Tumor suppressors and oncogenes with prognostic
potential. Curr Med Chem. 23:3136–3153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsai MM, Wang CS, Tsai CY, Huang HW, Chi
HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and
therapeutic targets of MicroRNAs in human gastric cancer. Int J Mol
Sci. 17:E9452016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu DY, Li XN, Qi Y, Liu DL, Yang Y, Zhao
J, Zhang CY, Wu K and Zhao S: miR-454 promotes the progression of
human non-small cell lung cancer and directly targets PTEN. Biomed
Pharmacother. 81:79–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang B, Zhu J, Wang Y, Geng F and Li G:
miR-454 inhibited cell proliferation of human glioblastoma cells by
suppressing PDK1 expression. Biomed Pharmacother. 75:148–152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu L, Gong X, Sun L, Yao H, Lu B and Zhu
L: miR-454 functions as an oncogene by inhibiting CHD5 in
hepatocellular carcinoma. Oncotarget. 6:39225–39234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu L, Nie J, Chen L, Dong G, Du X, Wu X,
Tang Y and Han W: The oncogenic role of microRNA-130a/301a/454 in
human colorectal cancer via targeting Smad4 expression. Plos One.
8:e555322013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou L, Qu YM, Zhao XM and Yue ZD:
Involvement of miR-454 overexpression in the poor prognosis of
hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 20:825–829.
2016.PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niu G, Li B, Sun J and Sun L: miR-454 is
down-regulated in osteosarcomas and suppresses cell proliferation
and invasion by directly targeting c-Met. Cell Prolif. 48:348–355.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fuse N, Kuboki Y, Kuwata T, Nishina T,
Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, et
al: Prognostic impact of HER2, EGFR, and c-MET status on overall
survival of advanced gastric cancer patients. Gastric Cancer.
19:183–191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cappuzzo F, Marchetti A, Skokan M, Rossi
E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG,
Buttitta F, Incarbone M, Toschi L, et al: Increased MET gene copy
number negatively affects survival of surgically resected
non-small-cell lung cancer patients. J Clin Oncol. 27:1667–1674.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li B, Yang XX, Wang D and Ji HK:
MicroRNA-138 inhibits proliferation of cervical cancer cells by
targeting c-Met. Eur Rev Med Pharmacol Sci. 20:1109–1114.
2016.PubMed/NCBI
|
|
18
|
Baykal C and Ayhan A, Al A, Yüce K and
Ayhan A: Overexpression of the c-Met/HGF receptor and its
prognostic significance in uterine cervix carcinomas. Gynecol
Oncol. 88:123–129. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Refaat T, Donnelly ED, Sachdev S, Parimi
V, El Achy S, Dalal P, Farouk M, Berg N, Helenowski I, Gross JP, et
al: c-Met overexpression in cervical cancer, a prognostic factor
and a potential molecular therapeutic target. Am J Clin Oncol 2015.
in press.
|
|
20
|
Organ SL and Tsao MS: An overview of the
c-MET signaling pathway. Ther Adv Med Oncol. 3(1 Suppl): S7–S19.
2011. View Article : Google Scholar : PubMed/NCBI
|
